Connect your AI

Nektar Therapeutics NKTR Gross Profit

Gross Profit at other companies

AmgenAMGN

$5.87B+13.4%

Iovance Biotherapeutics, Inc.IOVA

$28.93M+338%

Johnson & JohnsonJNJ

$15.96B+9.8%

ImmunityBio, Inc.IBRX

——

IncyteINCY

——

Other financials

Income statement

Revenue$10.9M+3.8%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

Market cap$2.25B+1,531%

Enterprise value$2.33B+874%

P/S40.5×+38.9×

Profitability

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Calculated from Nektar Therapeutics’s reported figures.

$21.8Mtotal revenue−-total cost of revenue=$21.81M

The official record: Nektar Therapeutics’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nektar Therapeutics's gross profit?: Nektar Therapeutics (NKTR) reported gross profit of $21.81M in Q4 2025.
How has Nektar Therapeutics's gross profit changed year-over-year?: Nektar Therapeutics's gross profit increased by 2.9% year-over-year, from $21.2M to $21.81M.
What is the long-term trend for Nektar Therapeutics's gross profit?: Over 4 years (2021 to 2025), Nektar Therapeutics's gross profit has grown at a -8.0% compound annual growth rate (CAGR), from $77.01M to $55.23M.
What does gross profit mean?: Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.